A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (RevlimidŽ) Regimen or a Sequential Azacitidine (VidazaŽ) Plus Lenalidomide (RevlimidŽ) Regimen Versus an Azacitidine (VidazaŽ) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
The aim of the study is to investigate the effect of a lenalidomide regimen, a sequential azacitidine plus lenalidomide regimen or an azacitidine regimen in elderly subjects 65 years or older with newly diagnosed AML.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Azacitidine-single agent
- drug : Lenalidomide - single agent
- drug : Lenalidomide in combination with azacitidine
Phase: Phase 2
Ages Eligible For Study:
- Newly diagnosed acute myeloid leukemia (AML), AML with antecedent hematologic disorder or therapy-related AML - Male or female subjects aged ? 65 - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - White blood cell (WBC) count ? 10 x 10?/L at screening